[Criteria of the eligibility of patients for treatment with intravenous normal human immunoglobulin].
Feugier
P
P
Service d'hématologie adulte, CHU Brabois, allée du Morvan, 54511 Vandoeuvre, France. p.feugier@chu-nancy.fr
Tomowiak
C
C
Daguindau
N
N
Perrot
A
A
D000367:Age Factors; D000368:Aged; D015331:Cohort Studies; D003627:Data Interpretation, Statistical; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use*; D007239:Infections / Q000150:complications; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy*; D008137:Longitudinal Studies; D008297:Male; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D018579:Patient Selection; D012737:Sex Factors; D013997:Time Factors
D016756:Immunoglobulins, Intravenous